Fate Therapeutics (FATE) Amortizatization of Intangibles (2012 - 2026)
Fate Therapeutics (FATE) posted Amortizatization of Intangibles of $772000.0 for Q1 2026, down 12.37% on a QoQ basis from $881000.0 in Q4 2025, and down 27.72% year-over-year from $1.1 million in Q1 2025.
Fate Therapeutics (FATE) Amortizatization of Intangibles (2012 - 2026) Analysis & Trends
Fate Therapeutics' Amortizatization of Intangibles history runs 12 years deep, the most recent figure standing at $772000.0 for Q1 2026.
- Quarterly Amortizatization of Intangibles fell 27.72% year-over-year to $772000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (down 55.97% YoY) and the FY2025 annual result came in at $3.6 million, down 60.29% from the prior year.
- Amortizatization of Intangibles was $772000.0 for Q1 2026 at Fate Therapeutics, down from $881000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $3.3 million in Q3 2023 and bottomed at -$873000.0 in Q1 2022.
- A 5-year average of $1.5 million and a median of $1.2 million in 2022 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles soared 696.33% — and 2025, when it sank 68.89%.
- Fate Therapeutics' Amortizatization of Intangibles stood at $1.2 million in 2022, then soared by 133.41% to $2.9 million in 2023, then slumped by 47.35% to $1.5 million in 2024, then sank by 42.42% to $881000.0 in 2025, then decreased by 12.37% to $772000.0 in 2026.
- Business Quant data shows FATE's Amortizatization of Intangibles at $772000.0 in Q1 2026, $881000.0 in Q4 2025, and $810000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 3.22 Mn |
| 10 | Fate Therapeutics | 288.82 Mn | 288.82 Mn | - | 772,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 772,000.00 |
| Mar 31, 2026 | 772,000.00 |
| Dec 31, 2025 | 881,000.00 |
| Dec 31, 2025 | 881,000.00 |
| Sep 30, 2025 | 810,000.00 |
| Sep 30, 2025 | 810,000.00 |
| Jun 30, 2025 | 847,000.00 |
| Jun 30, 2025 | 847,000.00 |
| Mar 31, 2025 | 1.07 Mn |
| Mar 31, 2025 | 1.07 Mn |
| Dec 31, 2024 | 1.53 Mn |
| Dec 31, 2024 | 1.53 Mn |
| Sep 30, 2024 | 2.20 Mn |
| Sep 30, 2024 | 2.20 Mn |
| Jun 30, 2024 | 2.72 Mn |
| Jun 30, 2024 | 2.72 Mn |
| Mar 31, 2024 | 2.63 Mn |
| Mar 31, 2024 | 2.63 Mn |
| Dec 31, 2023 | 2.91 Mn |
| Dec 31, 2023 | 2.91 Mn |